Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 180 participants.

Also called NCT07527650

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07527650
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07527650. Randomized; triple masking; primary purpose treatment. Start 2026-05-18 (actual); primary completion 2027-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Condition
T2DM
Intervention (Drug)
HM15275
Intervention (Drug)
Placebo of HM15275
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct07527650
Content hash
4723fb38e053b0aedc9a70fd662be09e8c7fbc0fa05253af1fcfd0c984d7df6e